AHA GUIDELINES Bundle (free trial)

Dyslipidemia 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1543908

Contents of this Issue

Navigation

Page 76 of 105

77 Table 22. Antiretroviral Therapy and Statin Drug Interactions (cont'd) Statin Antiretroviral Drug Recommendations Integrase Strand Transfer Inhibitors Atorvastatin Bictegravir Dolutegravir Raltegravir No dose adjustment needed. Elvitegravir/cobicistat Titrate statin dose carefully and administer the lowest effective dose while monitoring adverse events. Do not exceed atorvastatin 20 mg daily. Lovastatin Bictegravir Dolutegravir Raltegravir No dose adjustment needed. Elvitegravir/cobicistat Contraindicated. Pitavastatin Pravastatin Bictegravir Dolutegravir Raltegravir No dose adjustment needed. Elvitegravir/cobicistat No data available for dose recommendation. Rosuvastatin Bictegravir Dolutegravir Raltegravir No dose adjustment needed. Elvitegravir/cobicistat Titrate statin dose carefully and use the lowest effective dose while monitoring for adverse events. Simvastatin Bictegravir Dolutegravir Raltegravir No dose adjustment needed. Elvitegravir/cobicistat Contraindicated. NNRTI indicates non-nucleoside reverse transcriptase inhibitor; and NRTI, nucleoside reverse transcriptase inhibitor. Adapted from and modified with permissions from Sarkar et al. Copyright © 2000–2025 MDText.com, Inc.

Articles in this issue

Links on this page

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Dyslipidemia 2026